Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021.

Yue ZhouHuseyin NaciDingyi ChenLin BaiLu-Wen Shi Xiaodong GuanAnita Katharina Wagner

Published in: BMJ global health (2023)

While WHO has defined approval criteria for cancer drugs EML, we identified areas where adherence of these criteria and communication of the EML approval decision-making processes can be improved.

Keyphrases

papillary thyroid
decision making
squamous cell
lymph node metastasis
type diabetes
squamous cell carcinoma
childhood cancer
young adults
metabolic syndrome
weight loss
skeletal muscle
free survival